hero image

Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine

April 28, 2023 Company Statements

Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in early-stage Alzheimer’s disease (AD).

These early stage data support our commitment to building on a deep expertise in Alzheimer’s Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets.

A link to the manuscript is provided here: https://www.nature.com/articles/s41591-023-02326-3

Currently, the Phase 2 CELIA study of BIIB080 (NCT05399888) is in progress and recruiting participants in the United States.

In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).




February 13, 2024
Biogen Reports Fourth Quarter and Full Year 2023 Results
February 12, 2024
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients